Latest Breaking News On - Wayne pisano - Page 4 : comparemela.com

Beneath a Covid Vaccine Debacle, 30 Years of Government Culpability

Washington has rejected plans to revamp vaccine preparedness for decades and repeatedly paid a price. The Biden administration is at a similar crossroads.

New yorkUnited statesUnited kingdomNorth carolinaWhite houseDistrict of columbiaNew york stock exchangePine bluffState of michiganCapitol hillTimothy belskiAstrazeneca covidFrank rapoportWayne pisanoSaddam husseinDavid kessler

IMV Inc (IMV) Q1 2021 Earnings Call Transcript

Operator Good morning, and thank you for standing by. Welcome to the IMV Inc. first-quarter 2021 conference call. [Operator instructions] I would now like to hand the conference over to Pierre Labbé, chief financial officer. Thank you. Please go ahead. Pierre Labbe Chief Financial Officer Thank you, Takke. Good morning, everyone. My name is Pierre Labbé, CFO at IMV, and I m pleased to welcome you to our clinical and operational update and first-quarter financial results conference call. I m joined today by Fred Ors, our chief executive officer; and Andrew Hall, our chief business officer, who will be available for the question-and-answer period at the end of the call.

United statesWayne pisanoKaveri pohlmanMichael kalosTed tenthoff piper sandlerEli lillyPierre labbMerck keytrudaYves fradetChelsea stellickAndrew hallJoanne schindlerPiper sandlerTom shraderKyle kuvalankaJames hall

IMV Inc Announces First Quarter 2021 Financial and Operational Results and Expansion of its Clinical Pipeline

Press release content from Business Wire. The AP news staff was not involved in its creation. IMV Inc. Announces First Quarter 2021 Financial and Operational Results and Expansion of its Clinical Pipeline May 12, 2021 GMT DARTMOUTH, Nova Scotia (BUSINESS WIRE) May 12, 2021 IMV Inc. (the “Company” or “IMV”) (TSX: IMV; NASDAQ: IMV), a clinical-stage biopharmaceutical company pioneering a novel class of immunotherapies, today announced its financial and operational results for the first quarter ended March 31, 2021. “We remain focused on our commitment to provide effective and well-tolerated immunotherapies for patients with difficult-to-treat cancers. Clinical programs with our lead immunotherapy are progressing as expected, and we are pleased that maveropepimut-S will soon be evaluated in subjects with HR+/HER2- breast cancer, another unmet medical need,” announced Fred Ors, Chief Executive Officer at IMV. “We are reaching another milestone as our second immunother

United statesWayne pisanoJoanne schindlerMandy sheldonMichael kalosEli lillyKyle kuvalankaJames hallMarc jasminYves fradetDelphine davanSociety for immunotherapy of cancerProvidence cancer institute in portlandFred orsChief executive officerAnniversary annual meeting

IMV Inc (IMV) Names Kyle Kuvalanka to Board

IMV Inc (IMV) Names Kyle Kuvalanka to Board
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

Kyle kuvalankaWayne pisanoMandy sheldonSyros pharmaceuticals nasdaqTakeda oncology companyWharton school of the university pennsylvaniaBusiness developmentWesleyan universityChief financial officerChief operating officerGoldfinch bioFred orsChief executive officerBoard chairmanThird rock venturesPrincipal financial

IMV Appoints Kyle Kuvalanka to Board of Directors

IMV Appoints Kyle Kuvalanka to Board of Directors
biospace.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from biospace.com Daily Mail and Mail on Sunday newspapers.